A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Catherine Knupp Biography and Net Worth

EVP of Zoetis

Dr. Catherine A. Knupp is Executive Vice President, President - Research and Development of Zoetis Inc. Dr. Knupp has served as our Executive Vice President and President of Research and Development since October 2012. From 2005 to 2012, she served as Vice President of Pfizer’s Veterinary Medicine Research and Development business unit. Dr. Knupp joined Pfizer in July 2001 and held various positions, including Vice President of Pfizer’s Michigan laboratories for Pharmacokinetics, Dynamics and Metabolism.

What is Catherine A. Knupp's net worth?: The estimated net worth of Catherine A. Knupp is at least $7.80 million as of August 13th, 2020. Dr. Knupp owns 53,368 shares of Zoetis stock worth more than $7,801,868 as of April 19th. This net worth estimate does not reflect any other assets that Dr. Knupp may own. Learn More about Catherine A. Knupp's net worth.
How do I contact Catherine A. Knupp?: The corporate mailing address for Dr. Knupp and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Catherine A. Knupp's contact information.
Has Catherine A. Knupp been buying or selling shares of Zoetis?: Catherine A. Knupp has not been actively trading shares of Zoetis during the past quarter. Most recently, Catherine A. Knupp sold 13,000 shares of the business's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $158.86, for a transaction totalling $2,065,180.00. Following the completion of the sale, the executive vice president now directly owns 53,368 shares of the company's stock, valued at $8,478,040.48. Learn More on Catherine A. Knupp's trading history.
Who are Zoetis' active insiders?: Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.
Are insiders buying or selling shares of Zoetis?: In the last twelve months, insiders at the sold shares 13 times. They sold a total of 46,408 shares worth more than $8,362,102.41. The most recent insider tranaction occured on April, 18th when EVP Roxanne Lagano sold 923 shares worth more than $139,529.91. Insiders at Zoetis own 0.1% of the company. Learn More about insider trades at Zoetis.
Information on this page was last updated on 4/18/2024.

Catherine A. Knupp Insider Trading History at Zoetis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/13/2020	Sell	13,000	$158.86	$2,065,180.00	53,368
11/27/2019	Sell	28,563	$119.91	$3,424,989.33	78,616
3/5/2019	Sell	32,767	$95.80	$3,139,078.60	82,820
8/15/2018	Sell	46,816	$90.84	$4,252,765.44	81,640
5/12/2017	Sell	5,785	$60.16	$348,025.60	24,415

Catherine A. Knupp Buying and Selling Activity at Zoetis

Zoetis Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Today's Range

Now: $146.45

$145.83

$151.50

50 Day Range

MA: $175.48

$146.45

$199.94

2 Week Range

Now: $146.45

$145.80

$201.92

Volume

6,228,766 shs

Average Volume

3,032,044 shs

Market Capitalization

$66.98 billion

P/E Ratio

28.89

Dividend Yield

1.14%

Beta

0.85

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad